Journals / Ege Pediatri Bülteni / 2007 / Cilt: 14 - Sayı: 3

Advanced therapy for juvenile ıdiopathic arthritis

Juvenil idiopatik artrit’de tedavi yaklaşımları

Pages
195–202
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article is reviewed in three sections: pharmacologic therapy, physiotherapy and support therapies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Juvenile idiopathic arthritis (JIA), characterized principally by arthritis of the peripheral joints, is considered to be closely related with activation of immune system by contact with an exogenous or endogen antigen.
📊
Key Findings & Data:The goal of therapy is to control pain, preserve joint range of motion and function, minimize systemic complications, and assist in normal growth and development.
💡
Conclusion & Impact:This article is reviewed in three sections: pharmacologic therapy, physiotherapy and support therapies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Juvenile idiopathic arthritis (JIA), characterized principally by arthritis of the peripheral joints, is considered to be closely related with activation of immune system by contact with an exogenous or endogen antigen. The goal of therapy is to control pain, preserve joint range of motion and function, minimize systemic complications, and assist in normal growth and development. Recent advances in understanding the pathophysiology of arthritis have expanded the treatment of this chronic condition. Many medications including non steroidal anti inflammatory agents (NSAIDs), disease-modifying anti rheumatic drugs (DMARDs), biologic response modifiers (BRM) (Etanercept, Infliximab, Adalimumab, or Anakinra) and cytotoxic agents are available for treating juvenile rheumatoid arthritis. Multidisciplinary team management for children with JIA focusing on the physical, nutritional, intellectual and psychosocial wellbeing of the child is important. This article is reviewed in three sections: pharmacologic therapy, physiotherapy and support therapies.

Özet

Juvenil idiopatik artrit (JIA), ağırlıklı olarak periferik eklemleri tutan, endojen ve eksojen antijenlerin etkileşimi sonucu bağışıklık sisteminin aşırı aktivasyonu ile seyreden bir hastalıktır. Tedavinin amacı, ağrının kontrolünün yanı sıra eklem fonksiyonlarının devamlılığını sağlamak, sistemik komplikasyonları azaltmak ve normal büyüme ve gelişimi sağlamaktır. Bu amaçla steroid olmayan anti inflamatuarlar (NSAII), hastalık modifiye edici ilaçlar (DMARD), immunosupresifler ve biyolojik tedavi ajanları (Etanercept, Infliximab, Adalimumab, ya da Anakinra) kullanılmaktadır. Tedavide multidisipliner yaklaşım hastanın fiziksel, entelektüel ve psikososyal gelişimi açısından oldukca önem taşır. Bu makale, farmakolojik tedavi, fizik egzersizler ve destek tedaviler olmak üzere üç ayrı başlık halinde aktarılacaktır

🔖

Cite This Article

KÜTÜKÇÜLER, N., YENİAY, S. B. (2022). Advanced therapy for juvenile ıdiopathic arthritis. Ege Pediatri Bülteni, Cilt: 14 - Sayı: 3, 195–202. https://ajindex.com/articles/495710

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392
  2. Wallace CA, Ruperto N, Giannini E. Childhood Arthritis and Rheumatology Research Alliance; the Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis (JIA). The Journal Rheumatology 2004; 31: 2290–2294
  3. Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol 1992;19: 6-10
  4. Hashkes JP, Laxer RM. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA 2005, 294;13:1671-1684
  5. Fresko I. Romatizmal hastalıklarda tedavi. IU Cerrahpaşa Tıp Fakültesi, Sürekli Tıp Eğitimi Etkinlikleri, Romatizmal hastalıklar Sempozyumu,1999 s:45-54
  6. Kenan GF, Gianni EH, Athreya BH. Clinically significant gastropathy associated with nonsteroidal anti-inflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol1995,22:1149-1151
  7. Mehta S, Lang B. Long –term follow-up of naproxen- induced pseudoporphyria in juvenile rheumatoid arthritis. Arthritis Rheum.1999;42:2252-2254
  8. Petty RE, Cassidy JT. Juvenile idiopathic arthritis.In: Cassidy JT, Petty RE (eds) Textbook of Pediatric Rheumatology. WB Saunders Company 2001:214-217
  9. Cassidy JT, Petty RE. Juvenile rheumatoid arthritis.In: Cassidy JT, Petty RE (eds) Textbook of Pediatric Rheumatology. WB Saunders Company 2001:218-319
  10. Kasapcopur Ö, Arısoy N. Juvenil idiopatik artrit.Türk Pediatri Arşivi.2003;38:8-19
  11. Eberhard BA, Sison MC, Gottlieb BS and Ilowite NT. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis.The Journal of Rheumatology 2004; 31: 2507–2512
  12. Davis PJC, McDonagh JE. Management of paediatric musculoskeletal conditions in children and young women. Best Practice & Res. Clin. Rheumatol.2006: 20: 263–278 13. Chakravarty K, Pharoah PDP & Scott DGI. A randomised controlled trial of post-injection rest following steroid therapy for knee synovitis. British Journal of Rheumatology 1994; 33: 464–468
  13. Gondwe JS, Davidson JE, Deeley S et al. Secondary Cushing’s syndrome in children with juvenile idiopathic arthritis following intraarticular triamcinolone acetonide administration. Rheumatology 2005; 44: 1457–1458. 15.